浙江泰林生物技术股份有限公司 关于取得专利证书及计算机软件著作权登记证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）、浙江泰林分析仪器有限公司（以下简称"泰林分析仪 器"）于近期共取得了 3 项专利证书以及 1 项计算机软件著作权登记证书，具体 情况如下： 证券代码：300813 证券简称：泰林生物 公告编号：2025-086 浙江泰林生物技术股份有限公司董事会 2025 年 12 月 31 日 上述专利证书的取得不会对公司及全资子公司泰林医学工程、泰林生命科学 近期生产经营产生重大影响，但有利于公司及全资子公司泰林医学工程、泰林生 命科学进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新 机制，保持技术领先地位，提升核心竞争力。 上述计算机软件著作权登记证书的取得不会对公司及全资子公司泰林分析 仪器近期生产经营产生重大影响，但在一定程度上有利于发挥公司及全资子公司 泰 ...

（来源：泰林生物） 2025年10月29日，"微生物快速检测分析仪省级工业新产品验收评审会"在浙江泰林分析仪器有限公司隆重举行。本次会议邀请多位行业资深专家组成评审 团，由杭州市经信局技创处工作人员主持并介绍专家组成员。 评审会现场，公司项目核心团队向专家组全面展示了产品的技术创新与核心优势。在专家组质询与讨论环节，各位专家就技术细节、应用前景等进行了深 入而严谨的提问，公司技术团队一一作出了详实、专业的解答，其卓越性能获得了专家组的一致高度评价。最终，专家组经过闭门评议，顺利形成验收通 过意见。会议最后，由泰林生物副总裁夏信群先生作总结发言，向与会领导及专家的指导表示了衷心感谢。 权威评审，现场见证产品硬实力 技术引领，破解行业检测瓶颈 此次成功通过验收并入选的优秀产品——MD500型微生物快速检测分析仪，是泰林分析针对制药、半导体、食品等行业微生物检测痛点研发的核心成 果。它成功突破传统培养法72小时的滞后瓶颈，创新采用激光诱导荧光+米氏散射技术，可实现对水中微生物的实时、精准监测，符合中国药典、GMP及 欧美GMP对检测时效性与数据可靠性的严苛要求。 作为国家高新技术企业，泰林分析始终以"技术创新驱动产 ...

Core Insights - The 2025 Second Forum on High-Quality Water Production and Supply was successfully held in Jinan from December 8-10, featuring participation from various prestigious institutions and companies in the water sector [1][10] Group 1: Event Overview - The forum included case sharing on high-quality water production, supply, disinfection, and water safety monitoring from institutions like Harbin Institute of Technology, Tongji University, Tsinghua University, and others [1][10] - The event showcased the collaboration between TaiLin and Jiangsu Hongzhong Baide Biotechnology Co., focusing on accelerating smart water quality monitoring [3][12] Group 2: Product Showcase - TaiLin exhibited a range of products including intelligent analyzers for algae and two worms, automated detection systems, and microbiological testing equipment, emphasizing accurate and efficient water quality detection [3][12] - The product lineup included enzyme substrate method microbiological automatic counting instruments and sampling bottles, aimed at enhancing water quality analysis technology [3][12] Group 3: Technological Insights - Manager Ling provided an in-depth analysis of the core value of smart monitoring technology in ensuring drinking water safety, presenting TaiLin's innovative water ecological detection product system and its applications [6][17] - The company has developed a comprehensive product matrix covering online monitoring, portable detection, and emergency response, creating a full-chain solution from source warning to incident response [6][17] Group 4: Presentation Highlights - During a special report session, Manager Ling delivered a presentation titled "Smart Monitoring Empowers Drinking Water Safety: TaiLin Water Ecological Detection Products and Full-Scene Applications" [7][15] - The presentation highlighted how TaiLin utilizes enzyme substrate methods and intelligent analyzers to transition drinking water safety management from passive response to proactive warning, demonstrating significant improvements in monitoring efficiency and cost reduction [9][19]

浙江泰林生物技术股份有限公司 关于取得专利证书的公告 证券代码：300813 证券简称：泰林生物 公告编号：2025-085 特此公告。 浙江泰林生物技术股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 12 月 5 日 | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种电动安瓿瓶开瓶装置 | 发明 | 2023111810779 | 2025/11/28 | 泰林生命科学 | | 2 | 一种气路底板充气装置充气的方 | 发明 | 2022106176736 | 2025/11/28 | 泰林分析仪器 | | | 法 | | | | | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林分析仪器近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林分析仪 器进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制， 保持技术领先地位，提升核心竞争力。 浙江泰林生物技术股份 ...

Core Viewpoint - TaiLin Bio's stock price has shown volatility, with a year-to-date increase of 56.12%, but a recent decline over the past 20 and 60 days, indicating potential market fluctuations and investor sentiment changes [1]. Financial Performance - For the period from January to September 2025, TaiLin Bio reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit attributable to shareholders was 14.72 million yuan, reflecting a year-on-year increase of 30.13% [2]. - Cumulative cash dividends since the company's A-share listing amount to 117 million yuan, with 60.1 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.61% to 9,437, while the average circulating shares per person increased by 15.76% to 8,058 shares [2]. - Notably, the fund "Noan Multi-Strategy Mixed A" has exited the list of the top ten circulating shareholders [3]. Market Activity - On November 28, TaiLin Bio's stock price fell by 2.02% to 26.65 yuan per share, with a trading volume of 19.08 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 3.23 billion yuan [1]. - The net inflow of main funds was 1.1 million yuan, with large orders accounting for 15.25% of purchases and 9.49% of sales [1].

Core Viewpoint - Tailin Bio (300813) responded to investor inquiries on the interactive platform, indicating that specific shareholder information can be found in the company's disclosed periodic reports [1] Group 1 - The company provided a response regarding shareholder information [1]

Core Insights - The stock price of Tailin Biological closed at 27.2 yuan on November 27, with a 4.90% increase, resulting in a rolling PE ratio of 200.29 times and a total market capitalization of 3.297 billion yuan [1] - The average PE ratio in the medical device industry is 51.68 times, with a median of 40.10 times, placing Tailin Biological at the 114th position in the industry ranking [1] - As of September 30, 2025, the number of shareholders for Tailin Biological decreased by 1,487 to 9,437, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures, providing high-quality products and solutions for various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The company has a portfolio of 419 technology patents, including 55 invention patents, and has participated in the formulation of 35 national and industry standards, with 17 of those as the first author [2] - Tailin Biological has undertaken three key projects under the "13th Five-Year National Science and Technology Innovation Plan" and received an award for technological innovation from the China Pharmaceutical Equipment Industry Association [2] Financial Performance - In the latest quarterly report for Q3 2025, Tailin Biological reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit increased by 30.13% to 14.7233 million yuan, with a gross profit margin of 52.59% [2]

Core Viewpoint - Tailin Bio (300813.SZ) announced that its wholly-owned subsidiary, Tailin Analytical Instruments, has recently obtained a software copyright registration certificate for its software "Total Organic Carbon Detection Analysis and Data Processing Software V1.0" [1] Summary by Relevant Sections - **Software Copyright Registration** - The software copyright registration certificate number is 16842943, and the registration number is 2025SR2186745 [1] - **Impact on Operations** - The acquisition of the software copyright will not have a significant impact on the company's and its subsidiary's recent production and operations [1] - **Strategic Advantages** - This achievement is expected to enhance the company's and its subsidiary's intellectual property advantages, improve the intellectual property protection system, foster a continuous innovation mechanism, and elevate core competitiveness [1]

浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 分析仪器有限公司（以下简称"泰林分析仪器"）于近期共取得了 1 项计算机软 件著作权登记证书，具体情况如下： | 序号 | 软件名称 | 著作权人 | 证书号 | 首次发表日 期 | 登记日期 | 权利 取得 | 权利 范围 | 登记号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 方式 | | | | | 总有机碳 | | | | | | | | | | 检测分析 | 泰林分析 | 软著登字第 | | | 原始 | 全部 | 2025SR21 | | 1 | 与数据处 | | 16842943 | 2025/7/22 | 2025/11/12 | | | | | | 理软件 | 仪器 | 号 | | | 取得 | 权利 | 86745 | | | V1.0 | | | | | | | | 上述计算机软件著作权登记证书的取得不会对公司及全资子公司泰林分析 仪器近期生产经营产生重大影响，但在一定程度上有利于发挥公司及全资子公司 泰林分析仪器的自主知 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-083 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）于近期共取得了 3 项专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种过氧化氢汽化消毒机 | 实用新型 | 2024225569186 | 2025/11/7 | 泰林医学工程 | | 2 | 一种西林瓶翻转装置 | 实用新型 | 2024227562302 | 2025/11/7 | 泰林医学工程 | | 3 | 一种多用途的虹吸旋盖 | 实用新型 | 2024232559916 | 2025/11/7 | 泰林生命科学； 江苏宏众百德 生物科技有限 公司 | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林医学工程近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林医学工 程进一步完善知识产权保 ...